Health Dictionary Find a Doctor

Lymphadenopathy

Lymphadenopathy


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1],Shyam Patel [2];Associate Editor(s)-in-Chief: Amandeep Singh M.D.[3], Raviteja Guddeti, M.B.B.S. [4] Ogechukwu Hannah Nnabude, MD


Synonyms and keywords: Lymph nodes enlarged; Enlarged lymph nodes; Lymphadenitis; Swollen lymph nodes; Swollen/enlarged lymph nodes
For patient information, click here

Overview

Overview

Lymphadenopathy


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2],, Raviteja Guddeti, M.B.B.S. [3]Delband Yekta Moazami, M.D.[4]

Overview

Lymphadenopathy (also known as “enlarged lymph nodes”) refers to lymph nodes which are abnormal in size, number, or consistency. Common causes of lymphadenopathy are infection, autoimmune disease, or malignancy. Lymphadenopathy may be classified according to distribution into 2 groups: generalized lymphadenopathy and localized lymphadenopathy. The pathogenesis of lymphadenopathy is characterized by the inflammation of lymph nodes. This process is primarily due to an elevated rate of trafficking of lymphocytes into the node from the blood, exceeding the rate of outflow from the node. Lymph nodes may also be enlarged secondarily as a result of the activation and proliferation of antigen-specific T and B cells (clonal expansion). Lymphadenopathy is very common, the estimated incidence of lymphadenopathy among children in the United States ranges from 35%- 45%. Patients of all age groups may develop lymphadenopathy. Lymphadenopathy is more commonly observed among children. Common complications of lymphadenopathy, may include: abscess formation, superior vena cava syndrome, and intestinal obstruction. Diagnostic criteria for malignant lymphadenopathy, may include: node > 2 cm, node that is draining, hard, or fixed to underlying tissue, atypical location (e.g. supraclavicular node), associated risk factors (e.g. HIV or TB), fever and/or weight loss, and splenomegaly. On the other hand, diagnostic criteria for benign lymphadenopathy, may include: node < 1 cm, node that is mobile, soft-or tender, and is not fixed to underlying tissue, typical location (e.g. supraclavicular node), no associated risk factors, and palpable and painful enlargement. Laboratory findings consistent with the diagnosis of lymphadenopathy may include elevated lactate dehydrogenase (LDH), mild neutropenia, and leukocytosis. There is no treatment for lymphadenopathy; the mainstay of therapy is treating the underlying condition.

Historical Perspective

Classification

Lymphadenopathy may be classified according to distribution into 2 groups localized lymphadenopathy and generalized lymphadenopathy. Lymphadenopathy may be classified as follows:

Pathophysiology

Lymph nodes are part of the immune system. As such, they are most readily palpable when fighting infections. Infections can either originate from the organs that they drain or primarily within the lymph node itself, referred to as lymphadenitis.*The pathogenesis of lymphadenopathy is characterized by the inflammation of lymph nodes. This process is primarily due to an elevated rate of trafficking of lymphocytes into the node from the blood, exceeding the rate of outflow from the node.

  • The immune response between the antigen and lymphocyte that leads to cellular proliferation and enlargement of the lymph nodes.
  • Lymph nodes may also be enlarged secondarily as a result of the activation and proliferation of antigen-specific T and B cells (clonal expansion).
  • On gross pathology, characteristic findings of lymphadenopathy, include:
  • Enlarged lymph node
  • Soft greasy yellow areas within the capsule

Lymph nodes are a part of the reticuloendothelial (RES) system, which includes lymphatic vessels, the lymphatic fluid found in interstitial fluid, monocytes of the blood, macrophages of the connective tissue, bone marrow, thymus, spleen, bone, and mucosa-associated lymphoid tissue (MALT) of visceral organs Lymphatic fluid moves throughout the lymphatic system and enters lymph nodes for filtration of foreign antigen. Foreign antigens are presented to the lymphoid cells, which lead to cellular proliferation and enlargement. Under microscopy, cellular proliferation in lymphoid follicles may be identified as several mitotic figures. Increased activity leads to stretching of the lymphatic capsule and this may cause localized tenderness.

The development of B-cells originates from pluripotent stem cells from the bone marrow. B cells that successfully build their immunoglobulin heavy chains migrate to the germinal centers to allow for antibody diversification by somatic hypermutation. The current school of thought is that B-cell lymphomas occur as a result of alternations in chromosomal translocations and somatic hypermutation.

T-cell development also begins from pluripotent stem cells, which mature within the thymic cortex. While they are in the thymic cortex, specific rearrangements occur at the T-cell receptor. It is understood that chromosomal translocations at the level of T-cell receptors lead to T-cell lymphomagenesis.

Lymph nodes follicle necrosis may occur due to inflammatory, infectious, or malignant conditions. The neutrophil-rich infiltrates suggests bacterial infection, while lymphocyte-rich predominance may suggest viral infection. However, clinicians must remember that etiologies may vary; lymphomas, leukemias, tuberculosis, or even systemic lupus erythematosus (SLE) may be more appropriate diagnoses in the appropriate clinical context

Causes

The most common causes of lymphadenopathy include infections, cancers, and connective tissue disorders. Lymph node enlargement can be of viral, bacterial, malignant, protozoan origin and can even be caused by live vaccines Examples of infections that can cause lymph node enlargement include:

as well HHV8 and HIV.

Examples of malignancies that cause lymphadenopathy are:

Autoimmune causes include: systemic lupus erythematosus and rheumatoid arthritis may have generalized lymphadenopathy.

Benign lymphadenopathy

Examples include:

Axillary lymphadenopathy can be defined as solid nodes measuring more than 15  mm without fatty hilum. Axillary lymph nodes may be normal up to 30  mm if consisting largely of fat.

In children, a short axis of 8  mm can be used. However, inguinal lymph nodes of up to 15  mm and cervical lymph nodes of up to 20  mm are generally normal in children up to age 8–12.

Lymphadenopathy of more than 1.5  cm – 2  cm increases the risk of cancer or granulomatous disease as the cause rather than only inflammation or infection. Still, increasing size and persistence over time are more indicative of cancer.

Differentiating Lymphadenopathy from Other Diseases

Lymphadenopathy must be differentiated from syphilis, which may present as fever, myalgias, weight loss, and lymph node enlargement. After a thorough history and physical examination, lymphadenopathy can be initially categorized as:

Diagnostic: wherein the practitioner has a proximal cause for the lymph nodes and can go on to treat them. Examples would be Strep pharyngitis or localized cellulitis. The lymphadenopathy pattern history and physical examination can be suggestive an example would be mononucleosis wearing the practitioner has a strong clinic index of suspicion can perform a confirmatory test which if positive he can go on and treat the patient.

Unexplained lymphadenopathy. Unexplained lymphadenopathy can be generalized into localized or generalized lymphadenopathy. Unexplained localized lymphadenopathy is further divided into patterns at no risk for malignancy or severe illness in which case the patient can be observed for 3 to 4 weeks and if a response or improvement can be followed. The other alternative is if the patient is found to have a risk formalignancy or serious illness biopsy is indicated

Unexplained generalized lymphadenopathy can be approached after a review of epidemiological clues and medications with initial testing with a CBC with manual differential and mononucleosis serology if either is positive and diagnostic proceed to treatment. If both are negative, the second workup approach would be a PPD, and RPR, a chest x-ray, and ANA, hepatitis BS antigen serology and HIV. Additional testing modalities and lab tests may be indicated depending on clinical cues. If the results of this testing are conclusive, the practitioner can proceed on to diagnosis and treatment of the illness. If the results of the testing are still not clear, proceed to biopsy of the most abnormal of the nodes. The most functional way to investigate the differential diagnosis of lymphadenopathy is to characterize it by node pattern and location, obtained pertinent history including careful evaluation of epidemiology, and place the patient in the appropriate arm of the algorithm to evaluate lymphadenopathy.

Epidemiology and Demographics

The estimated incidence of lymphadenopathy in children in the United States ranges from 35%- 45%. It is more common in the pediatric population. Race and gender have no predilection in lymphadenopathy incidence. Generalities can safely be made about the epidemiology of lymphadenopathy. First, both generalized and localized lymphadenopathies are fairly equally distributed without regard to gender. Second, lymphadenopathy is more prevalent in the pediatric population than in the adult population secondary to the greater number of viral infections. It would follow that the majority of the time, lymphadenopathy in the pediatric population is of less consequence again secondary to the prevalence of viral and bacterial infections in that age group. Three-quarters of all lymphadenopathy observed are localized, and of those three-quarters, half of these are localized to the head and neck area. All remaining localized lymphadenopathy is found in the inguinal area and the remaining lymphadenopathy is found in the axilla in the supraclavicular area. Of note, the differential diagnosis of lymphadenopathy changes significantly with the age of the patient. Third, the patient’s location and circumstance are very revealing and lymphadenopathy. For example, in the developing world (sub-Saharan Africa, Southeast Asia, Indian subcontinent), exposure to parasites, HIV, and miliary TB are far more likely to be causes of generalized lymphadenopathy than in the United States and Europe. Whereas, Epstein-Barr virus, streptococcal pharyngitis, and some neoplastic processes are more likely candidates to cause lymphadenopathy in the United States and the remainder of the localized industrial world. An exposure history is very important for diagnosis. Exposure to blood and blood-borne products either through transfusion, unsafe sexual practices, intravenous drug abuse, or vocation Exposure to infectious disease whether it be travel, in the workplace, or the home Medication exposure-prescription, nonprescription, or supplements Exposure to animal-borne illness either via pets or the workplace Exposure to arthropod bites

Risk Factors

Common risk factors in the development of lymphadenopathy may be occupational, environmental, genetic, and viral.

Screening

There is insufficient evidence to recommend routine screening for lymphadenopathy

Natural History, Complications, and Prognosis

The natural course of lymphadenopathy depends on the underlying cause. Lymphadenopathy due to infectious causes subsides once the infection is controlled. Common complications of lymphadenopathy depend on the site of involvement, e.g. mediastinal lymphadenopathy include compression symptoms likeTracheal and bronchial obstruction and Dysphagia in Superior vena cava syndrome. Prognosis is generally excellent for infectious causes. Prompt treatment with antibiotics usually leads to a complete recovery. However, it may take weeks, or even months, for swelling to disappear. The amount of time to recovery depends on the cause. Prognosis is poor for malignant tumors.

Diagnosis

Diagnostic Criteria

Malignant Lymphadenopathy

Benign Lymphadenopathy

  • Node < 1 cm
  • Node that is mobile, soft-or tender, and is not fixed to underlying tissue
  • Common location (e.g. supraclavicular node)
  • No associated risk factors
  • Palpable and painful enlargement

History and Symptoms

The hallmark of lymphadenopathy is swollen lymph node. A positive history of a lump in the neck, red, tender skin over lymph node, and swollen, tender, or hard lymph nodes is suggestive of lymphadenopathy. The most common symptoms of lymphadenopathy include a lump in neck or affected part and constitutional symptoms like fatigue, fever, malaise, flu– like illness, nausea and vomiting, night sweats, weight loss, and cachexia.

Physical Examination

Common physical examination findings of lymphadenopathy include fever and tachycardia in infectious causes. There is an enlargement of different groups of lymph node chains depending upon the site of involvement and underlying causes.

Laboratory Findings

  • ANA: this is a screening test for SLE that can help establish it as a cause for generalized lymphadenopathy

Electrocardiogram

X-ray

Chest X-ray can reveal tuberculosis, pulmonary sarcoidosis, and pulmonary neoplasm.

Echocardiography and Ultrasound

Ultrasound can help in the diagnosis of lymphadenopathy to define the presence and extent of a lymph node abscess, to differentiate malignant lymph nodes from lymph node enlargement due to infections. On ultrasound, characteristic findings of lymphadenopathy, include increased lymph node size. In the assessment of number, size, form, marginal description, and internal structures in patients with lymphadenopathy, this imaging modality can be used. Furthermore, color Doppler ultrasonography is used to differentiate between older pre-existing lymphadenopathy and newly active lymphadenopathy in the vascular pattern.

CT scan

A Chest CT scan may be helpful in the diagnosis of hilar adenopathy. Findings on CT scan suggestive of/diagnostic of tuberculosis, sarcoidosis, lymphoma, and other malignancies. Abdominal and pelvic CT scan in combination with chest CT scan can be revealed in cases of supraclavicular adenopathy and the diagnosis of secondary neoplasm.

MRI

MRI may be helpful in the diagnosis of lymphadenopathy. Findings on MRI suggestive of/diagnostic of lymphadenopathy include negative enhancement that is showed as decreased T1 and T2 signal intensity.

Other Imaging Findings

Other Diagnostic Studies

Treatment

Treatment of lymphadenopathy is based on the etiology. Generally, treatment of lymphadenopathy is as follows:

  • If medication is the suspected cause, discontinue the medication if possible.

Medical Therapy

The medical therapy depends upon the underlying cause. Appropriate antibiotics are given for infective causes. Glucocorticoids for autoimmune conditions like sarcoidosis, and chemotherapy and radiation for malignant causes.

Surgery

Surgery is not the first-line treatment option for patients with lymphadenopathy. Surgery is usually reserved for patients with either malignancy and an indication of biopsy. It involves the removal or aspiration of lymph nodes. They are dissected when cancer is in an advanced stage.

Primary Prevention

Good general health and hygiene are helpful in the prevention of any infection.

Secondary Prevention

Effective measures for the secondary prevention of lymphadenopathy include sentinel lymph node biopsy and early treatment if metastasis is detected.

References

References

Template:WH Template:WS

Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2], Raviteja Guddeti, M.B.B.S. [3]Delband Yekta Moazami, M.D.[4] Ogechukwu Hannah Nnabude, MD

Overview

Lymphadenopathy may be classified according to distribution into 2 groups localized lymphadenopathy and generalized lymphadenopathy.

Classification

Depending upon the involvement of the lymph nodes, lymphadenopathy is classified into 2 groups, generalized and localized:[1]

  • Localized lymphadenopathy: localized adenopathy occurs in contiguous groupings of lymph nodes. In discrete anatomical regions, lymph nodes are distributed, and their enlargement represents their location’s lymphatic drainage. Tender or non-tender, fixed or mobile, and discreet or “matted” together can be the nodes themselves. 75 percent of all lymphadenopathies are localized, with over 50% seen in the region of the head and neck.

Lymphadenopathy may be classified as follows:

Upper limit of lymph node sizes in adults
Generally 10 mm[4][5]
Inguinal 10[6] – 20 mm[7]
Pelvis 10 mm for ovoid lymph nodes, 8 mm for rounded[6]
Neck
Generally (non-retropharyngeal) 10 mm[6][8]
Jugulodigastric lymph nodes 11mm[6] or 15 mm[8]
Retropharyngeal 8 mm[8]
Mediastinum
Mediastinum, generally 10 mm[6]
Superior mediastinum and high paratracheal 7mm[9]
Low paratracheal and subcarinal 11 mm[9]
Upper abdominal
Retrocrural space 6 mm[10]
Paracardiac 8 mm[10]
Gastrohepatic ligament 8 mm[10]
Upper paraaortic region 9 mm[10]
Portacaval space 10 mm[10]
Porta hepatis 7 mm[10]
Lower paraaortic region 11 mm[10]

References

  1. Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A (2014). “Peripheral lymphadenopathy: approach and diagnostic tools”. Iran J Med Sci. 39 (2 Suppl): 158–70. PMC 3993046. PMID 24753638.
  2. Ganeshalingam S, Koh DM (December 2009). “Nodal staging”. Cancer Imaging. 9: 104–11. doi:10.1102/1470-7330.2009.0017. PMC 2821588. PMID 20080453.
  3. Schmidt AF, Rodrigues OR, Matheus RS, Kim Jdu U, Jatene FB (2007). “Mediastinal lymph node distribution, size and number: definitions based on an anatomical study”. J Bras Pneumol. 33 (2): 134–40. doi:10.1590/s1806-37132007000200006. PMID 17724531.
  4. Ganeshalingam, Skandadas; Koh, Dow-Mu (2009). “Nodal staging”. Cancer Imaging. 9 (1): 104–111. doi:10.1102/1470-7330.2009.0017. ISSN 1470-7330. PMC 2821588. PMID 20080453.
  5. Schmidt Júnior, Aurelino Fernandes; Rodrigues, Olavo Ribeiro; Matheus, Roberto Storte; Kim, Jorge Du Ub; Jatene, Fábio Biscegli (2007). “Distribuição, tamanho e número dos linfonodos mediastinais: definições por meio de estudo anatômico”. Jornal Brasileiro de Pneumologia. 33 (2): 134–140. doi:10.1590/S1806-37132007000200006. ISSN 1806-3713. PMID 17724531.
  6. 6.0 6.1 6.2 6.3 6.4 6.5 Torabi M, Aquino SL, Harisinghani MG (September 2004). “Current concepts in lymph node imaging”. Journal of Nuclear Medicine. 45 (9): 1509–18. PMID 15347718.
  7. “Assessment of lymphadenopathy”. BMJ Best Practice. Retrieved 2017-03-04. Last updated: Last updated: Feb 16, 2017
  8. 8.0 8.1 8.2 Page 432 in: Luca Saba (2016). Image Principles, Neck, and the Brain. CRC Press. ISBN 9781482216202.
  9. 9.0 9.1 Sharma, Amita; Fidias, Panos; Hayman, L. Anne; Loomis, Susanne L.; Taber, Katherine H.; Aquino, Suzanne L. (2004). “Patterns of Lymphadenopathy in Thoracic Malignancies”. RadioGraphics. 24 (2): 419–434. doi:10.1148/rg.242035075. ISSN 0271-5333. PMID 15026591.
  10. 10.0 10.1 10.2 10.3 10.4 10.5 10.6 Dorfman, R E; Alpern, M B; Gross, B H; Sandler, M A (1991). “Upper abdominal lymph nodes: criteria for normal size determined with CT”. Radiology. 180 (2): 319–322. doi:10.1148/radiology.180.2.2068292. ISSN 0033-8419. PMID 2068292.

Template:WH Template:WS

Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Delband Yekta Moazami, M.D.[3] Ogechukwu Hannah Nnabude, MD

Overview

Lymph nodes are part of the immune system. As such, they are most readily palpable when fighting infections. Infections can either originate from the organs that they drain or primarily within the lymph node itself, referred to as lymphadenitis.

Pathophysiology

Lymph nodes are part of the immune system. As such, they are most readily palpable when fighting infections. Infections can either originate from the organs that they drain or primarily within the lymph node itself, referred to as lymphadenitis.The pathogenesis of lymphadenopathy is characterized by the inflammation of lymph nodes. This process is primarily due to an elevated rate of trafficking of lymphocytes into the node from the blood, exceeding the rate of outflow from the node.[1]

  • The immune response between the antigen and lymphocyte that leads to cellular proliferation and enlargement of the lymph nodes.
  • Lymph nodes may also be enlarged secondarily as a result of the activation and proliferation of antigen-specific T and B cells (clonal expansion).
  • On gross pathology, characteristic findings of lymphadenopathy, include:
  • Enlarged lymph node
  • Soft greasy yellow areas within the capsule

Lymph nodes are a part of the reticuloendothelial (RES) system, which includes lymphatic vessels, the lymphatic fluid found in interstitial fluid, monocytes of the blood, macrophages of the connective tissue, bone marrow, thymus, spleen, bone, and mucosa-associated lymphoid tissue (MALT) of visceral organs [1]

Lymphatic fluid moves throughout the lymphatic system and enters lymph nodes for filtration of foreign antigen. Foreign antigens are presented to the lymphoid cells, which lead to cellular proliferation and enlargement. Under microscopy, cellular proliferation in lymphoid follicles may be identified as several mitotic figures.[2] Increased activity leads to stretching of the lymphatic capsule and this may cause localized tenderness.

The development of B-cells originates from pluripotent stem cells from the bone marrow. B cells that successfully build their immunoglobulin heavy chains migrate to the germinal centers to allow for antibody diversification by somatic hypermutation.[3] The current school of thought is that B-cell lymphomas occur as a result of alternations in chromosomal translocations and somatic hypermutation.

T-cell development also begins from pluripotent stem cells, which mature within the thymic cortex. [4] While they are in the thymic cortex, specific rearrangements occur at the T-cell receptor. It is understood that chromosomal translocations at the level of T-cell receptors lead to T-cell lymphomagenesis.

Lymph nodes follicle necrosis may occur due to inflammatory, infectious, or malignant conditions. The neutrophil-rich infiltrates suggests bacterial infection, while lymphocyte-rich predominance may suggest viral infection. However, clinicians must remember that etiologies may vary; lymphomas, leukemias, tuberculosis, or even systemic lupus erythematosus (SLE) may be more appropriate diagnoses in the appropriate clinical context [5]

Microscopic findings

  • On microscopic histopathological analysis, characteristic findings of lymphadenopathy will depend on the etiology.Common findings, include:[1]

Non-specific reactive follicular hyperplasia (NSRFH)

  • Large spaced cortical follicles
  • Tingible body macrophages, normal dark/light GC pattern

Lymph node metastasis

Toxoplasmosis

Cat-scratch disease

Dermatopathic lymphadenopathy

Systemic lupus erythematosus lymphadenopathy

  • Blue hematoxylin bodies
  • Necrosis
  • No PMNs

Histology can provide more information regarding the cause of lymphadenopathy when etiology is not clear during initial history taking, physical examination, and laboratory evaluation.

Common causes of lymphadenopathy with their associated histological findings include:

References

  1. 1.0 1.1 1.2 Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A (2014). “Peripheral lymphadenopathy: approach and diagnostic tools”. Iran J Med Sci. 39 (2 Suppl): 158–70. PMC 3993046. PMID 24753638.
  2. Gowing NF (1974). “Tumours of the lymphoreticular system: nomenclature, histogenesis, and behaviour”. J Clin Pathol Suppl (R Coll Pathol). 7: 103–7. PMC 1347234. PMID 4598345.
  3. Mesin L, Ersching J, Victora GD (2016). “Germinal Center [[B Cell]] Dynamics”. Immunity. 45 (3): 471–482. doi:10.1016/j.immuni.2016.09.001. PMC 5123673. PMID 27653600. URL–wikilink conflict (help)
  4. Kumar BV, Connors TJ, Farber DL (2018) Human T Cell Development, Localization, and Function throughout Life. Immunity 48 (2):202-213. DOI:10.1016/j.immuni.2018.01.007 PMID: 29466753
  5. Strickler JG, Warnke RA, Weiss LM (1987). “Necrosis in lymph nodes”. Pathol Annu. 22 Pt 2: 253–82. PMID 3317224.
  6. Fend F, Cabecadas J, Gaulard P, Jaffe ES, Kluin P, Kuzu I; et al. (2012). “Early lesions in lymphoid neoplasia: Conclusions based on the Workshop of the XV. Meeting of the European Association of Hematopathology and the Society of Hematopathology, in Uppsala, Sweden”. J Hematop. 5 (3). doi:10.1007/s12308-012-0148-6. PMC 3845020. PMID 24307917.
  7. Elmore SA (2006) Histopathology of the lymph nodes. Toxicol Pathol 34 (5):425-54. DOI:10.1080/01926230600964722 PMID: 17067938
  8. Lucia HL, Griffith BP, Hsiung GD (1985) Lymphadenopathy during cytomegalovirus-induced mononucleosis in guinea pigs. Arch Pathol Lab Med 109 (11):1019-23. PMID: 2996461
  9. Eberle FC, Mani H, Jaffe ES (2009). “Histopathology of Hodgkin’s lymphoma”. Cancer J. 15 (2): 129–37. doi:10.1097/PPO.0b013e31819e31cf. PMID 19390308.

Template:WH Template:WS

Histopathology

Histopathology

Causes

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]Raviteja Guddeti, M.B.B.S. [3]Delband Yekta Moazami, M.D.[4] Ogechukwu Hannah Nnabude, MD

Overview

The most common causes of lymphadenopathy include infections, cancers, and connective tissue disorders. The enlargement of the lymph nodes may be of infectious, bacterial, malignant, protozoan origin and may also be caused by live vaccines. Viral infections such as Epstein-Barr virus and cytomegalovirus cause infectious mononucleosis. Yersinia pestis causes swelling of the lymph node so large that it can be seen under the skin, which causes the bubonic plague. These lymph nodes can become necrotic and are called buboes. Cat-scratch disease, cutaneous anthrax, and tuberculous lymphadenitis are other bacterial infections. African sleeping sickness, Chagas’ disease, and toxoplasmosis are protozoal infections. Neoplastic causes of lymphadenopathy are primary and secondary. Hodgkin lymphoma and non-Hodgkin lymphoma give lymphadenopathy in all or a few lymph nodes. Secondary: metastasis, Virchow’s Node, neuroblastoma, and chronic lymphocytic leukemia. Autoimmune causes include systemic lupus erythematosus and rheumatoid arthritis may have generalized lymphadenopathy.

Causes

Common Causes

Common causes of lymphadenopathy may include:

Causes by Organ System

Cardiovascular Apo a-i deficiency
Chemical/Poisoning Anthrax, Black widow spider venom, Zinc
Dental Lip cancer
Dermatologic Aphthous stomatitis, Asymmetric periflexural exanthem , Dermatomyositis, Erysipelas, Erythroderma, Gingivostomatitis, Infantile papular acrodermatitis, Leprosy, Mastitis, Measles, Melanoma, Mumps, Sarcoidosis, Spotted fevers, Yaws
Drug Side Effect Allopurinol, Atenolol, Bcg vaccine, Captopril, Carbamazepine, Cephalosporins, Certolizumab pegol, Hydralazine, Infliximab, Oxaprozin, Penicillin, Penicillium marneffei, Phenytoin, Pinta, Pneumococcal vaccine 13-valent  , Primidone, Pyrimethamine, Quinidine, Sulfonamides, Sulindac, Tiagabine, Typhoid vaccination
Ear Nose Throat Aphthous stomatitis, Kikuchi’s disease, Lymphangioma, Lymphangitis, Lymphatic filariasis, Lymphoma, Malignant lymphoma, Mesenteric adenitis, Sinus histiocytosis, Streptococcal pharyngitis, Vincent’s angina
Endocrine Castleman’s disease, Chediak-higashi syndrome, Hyperthyroidism
Environmental No underlying causes
Gastroenterologic Brucellosis, Colorectal cancer, Hemophagocytic lymphohistiocytosis, Stomach cancer, Whipple’s disease
Genetic Chediak-higashi syndrome, Churg-strauss syndrome, Faisalabad histiocytosis, Familial alphalipoprotein deficiency, Familial hemophagocytic lymphohistiocytosis, Familial histiocytic reticulosis, Griscelli disease, Lipogranulomatosis, Rosai-dorfman disease, Siccardi syndrome, Sphingomyelinase deficiency, Wt limb blood syndrome, X-linked agammaglobulinaemia, X-linked lymphoproliferative syndrome
Hematologic Acute lymphatic leukemia, Acute lymphoblastic leukemia, Acute lymphocytic leukemia, Addison’s disease, Adult t cell leukemia, Apo a-i deficiency, Autoimmune haemolytic anaemia, Autoimmune lymphoproliferative syndrome type 1, Caspase-8 deficiency, Chancroid, Chronic lymphatic leukemia, Chronic lymphocytic leukemia, Churg-strauss syndrome, Cutaneous t cell lymphoma, Familial alphalipoprotein deficiency, Familial hemophagocytic lymphohistiocytosis, Familial histiocytic reticulosis, Hairy cell leukaemia, Hemoblastosis, Histiocytosis x, Hodgkin’s lymphoma, Hyperimmunoglobulinemia d , Kawasaki disease, Large granular lymphocyte leukemia, Lassa fever, Leukemia, Macroglobulinemia, Myeloproliferative disorder, Non-hodgkin’s lymphoma, Plasma cell leukemia, Primary autoimmune haemolytic anaemia, Pseudolymphoma, Septicaemia, Siccardi syndrome, Sinus histiocytosis, Waldenström macroglobulinemia, Yersinia pestis
Iatrogenic Bcg vaccine, Pneumococcal vaccine 13-valent  , Radiotherapy, Typhoid vaccination
Infectious Disease Bacteria:

Anthrax, Borrelia burgdorferi, Boutonneuse fever, Brucellosis, Cat scratch disease, Congenital tuberculosis, Erysipelas, Granuloma inguinale, Lepromatous leprosy, Listeriosis, Lymphogranuloma venereum,Mastitis, Moraxella catarrhalis, Mycobacterium avium-intracellulare, Mycobacterium chelonei, Pinta,Plague, Rat-bite fever, Rickettsiae, Scrub typhus, Sennetsu fever, Septicaemia, Spotted fevers,Streptococcal tonsillitis, Syphilis, Three-day fever, Tuberculosis, Tularemia, Typhus fever, Vincent’s angina, Yaws, Yersinia pestis

Virus:

AIDS, Cowpox, Coxsackie virus, Cytomegalovirus infection, Dengue, German Measles/Rubella, Hepatitis A, Hepatitis B, Herpes simplex, Infectious mononucleosis, Influenza, Lassa fever, Measles, Mumps,Smallpox, Varicella, Western equine encephalitis

Fungal:

Coccidioidomycosis, Blastomycosis, Histoplasmosis, Sporotrichosis

Parasitic:

African Sleeping sickness, Chagas’ disease, Congenital Toxoplasmosis, Filaria, Lymphatic filariasis,Onchocerciasis, Opisthorchiasis, Paracoccidioidomycosis, Rhabditida Infections, Toxoplasmosis,Trypanosomiasis, Visceral leishmaniasis /Kala-azar, Wuchereria bancrofti

Musculoskeletal/Orthopedic Dermatomyositis, Rhabdomyosarcoma, Rheumatoid arthritis
Neurologic African sleeping sickness, Western equine encephalitis
Nutritional/Metabolic Lipogranulomatosis
Obstetric/Gynecologic Breast cancer, Lymphogranuloma venereum
Oncologic Acute lymphatic leukemia, Acute lymphoblastic leukemia, Acute lymphocytic leukemia, Addison’s disease, Adult t cell leukemia, Breast cancer, Chronic lymphatic leukemia, Chronic lymphocytic leukemia, Colorectal cancer, Cutaneous t cell lymphoma, Cystic hygroma, Epstein-barr virus, Gamma heavy chain disease, Granuloma inguinale, Hemangiopericytoma, Hodgkin’s lymphoma, Inflammatory pseudotumor, Kikuchi’s disease, Leukemia, Lip cancer, Lymphangioma, Lymphoma, Malignant lymphoma, Melanoma, Merkel cell carcinoma, Myeloproliferative disorder, Non-hodgkin’s lymphoma, Pancoast tumor, Plasma cell leukemia, Primary autoimmune haemolytic anaemia, Pseudolymphoma, Reticuloendotheliosis, Rhabdomyosarcoma, Secondary deposits from a local malignancy, Stomach cancer, Systemic mastocytosis, Waldenström macroglobulinemia
Ophthalmologic No underlying causes
Overdose/Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary Congenital tuberculosis, Extrinsic allergic alveolitis, Histoplasmosis, Pancoast tumor, Pneumoconiosis, Tuberculosis
Renal/Electrolyte No underlying causes
Rheumatology/Immunology/Allergy Amyloidosis, Extrinsic allergic alveolitis, Hemangiopericytoma, Hemophagocytic lymphohistiocytosis, Hemophagocytic reticulosis, Juvenile chronic arthritis, Rheumatoid arthritis, Rheumatoid disease, Still’s disease, Systemic lupus erythematosus
Sexual Aids, Bejel, Chancroid, Herpes simplex, Herpes virus 2, Hiv-1 disease, Human immunodeficiency virus, Secondary syphilis, Sexually transmitted diseases, Syphilis
Trauma Snake bite , Spider bite
Urologic Granuloma inguinale
Miscellaneous Tang hsi ryu syndrome
  • Common causes of lymphadenopathy, include:[3][4]
  • Infections (acute suppurative)
  • Reactive

Causes in Alphabetical Order

Various causes in alphabetical order:[5][6]


Bihilar Lymphadenopathy

References

  1. Chris Jennings (1993). “Understanding and Preventing AIDS: A Book for Everyone”.
  2. 2.0 2.1 Status and anamnesis, Anders Albinsson. Page 12
  3. Mohseni S, Shojaiefard A, Khorgami Z, Alinejad S, Ghorbani A, Ghafouri A (2014). “Peripheral lymphadenopathy: approach and diagnostic tools”. Iran J Med Sci. 39 (2 Suppl): 158–70. PMC 3993046. PMID 24753638.
  4. Lymph node enlargment. Wikipedia. https://en.wikipedia.org/wiki/Lymph_node Accessed on May 9, 2016
  5. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:77 ISBN 1591032016
  6. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:68 ISBN 140510368X
  7. Blum JA, Neumayr AL, Hatz CF (June 2012). “Human African trypanosomiasis in endemic populations and travellers”. Eur. J. Clin. Microbiol. Infect. Dis. 31 (6): 905–13. doi:10.1007/s10096-011-1403-y. PMID 21901632.
  8. Beukes CA, Thiart J (November 2012). “The incidence of human herpes virus-8 expression in lymph node biopsies from human immunodeficiency virus-positive patients”. Histopathology. 61 (5): 942–4. doi:10.1111/j.1365-2559.2012.04291.x. PMID 22716315.
  9. Mitsuhashi K, Shiseki M, Ishiyama M, Kondo T, Kazama H, Yasunami T, Okamura T, Yoshinaga K, Mori N, Teramura M, Masuda A, Motoji T (July 2011). “[Angioimmunoblastic T-cell lymphoma with marked polyclonal plasmacytosis in peripheral blood and bone marrow mimicking plasma cell leukemia]”. Rinsho Ketsueki (in Japanese). 52 (7): 563–9. PMID 21821991.
  10. Simonelli S, Gianazza E, Mombelli G, Bondioli A, Ferraro G, Penco S, Sirtori CR, Franceschini G, Calabresi L (January 2012). “Severe high-density lipoprotein deficiency associated with autoantibodies against lecithin:cholesterol acyltransferase in non-Hodgkin lymphoma”. Arch. Intern. Med. 172 (2): 179–81. doi:10.1001/archinternmed.2011.661. PMID 22271127.
  11. Simesen de Bielke MG, Yancoski J, Rocco C, Pérez LE, Cantisano C, Pérez N, Oleastro M, Danielian S (December 2012). “A missense mutation in the extracellular domain of Fas: the most common change in Argentinean patients with autoimmune lymphoproliferative syndrome represents a founder effect”. J. Clin. Immunol. 32 (6): 1197–203. doi:10.1007/s10875-012-9731-y. PMID 22752343.
  12. Schleenvoigt BT, Keller P, Stallmach A, Pletz MW (April 2012). “[African tick bite fever–rickettsiosis after holiday in South Africa]”. Dtsch. Med. Wochenschr. (in German). 137 (17): 891–3. doi:10.1055/s-0032-1304902. PMID 22511280.
  13. Roushan MR, Amiri MJ (April 2013). “Update on childhood brucellosis”. Recent Pat Antiinfect Drug Discov. 8 (1): 42–6. PMID 22812616.
  14. Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K, Dogan A, Habermann TM (November 2012). “The clinical spectrum of Castleman’s disease”. Am. J. Hematol. 87 (11): 997–1002. doi:10.1002/ajh.23291. PMC 3900496. PMID 22791417.
  15. Chondrogiannis K, Vezakis A, Derpapas M, Melemeni A, Fragulidis G (2012). “Seronegative cat-scratch disease diagnosed by PCR detection of Bartonella henselae DNA in lymph node samples”. Braz J Infect Dis. 16 (1): 96–9. PMID 22358366.
  16. 16.0 16.1 Reddy RR, Babu BM, Venkateshwaramma B, Hymavathi C (July 2011). “Silvery hair syndrome in two cousins: Chediak-Higashi syndrome vs Griscelli syndrome, with rare associations”. Int J Trichology. 3 (2): 107–11. doi:10.4103/0974-7753.90825. PMC 3250006. PMID 22223973. Vancouver style error: initials (help)
  17. Fantinato GT, Cestari Sda C, Afonso JP, Sousa LS, Enokihara MM (2011). “Do you know this syndrome? Chediak-Higashi syndrome”. An Bras Dermatol. 86 (5): 1029. PMID 22147054.
  18. Warnatz K, Voll RE (2012). “Pathogenesis of autoimmunity in common variable immunodeficiency”. Front Immunol. 3: 210. doi:10.3389/fimmu.2012.00210. PMC 3399211. PMID 22826712.
  19. 19.0 19.1 Goyal T, Varshney A (May 2012). “A rare presentation of erythrodermic mycosis fungoides”. Cutis. 89 (5): 229–32, 236. PMID 22768436.
  20. Caballes RL, Caballes-Ponce MG, Kim DU (February 1997). “Familial hemophagocytic lymphohistiocytosis (FHLH)”. Pathology. 29 (1): 92–5. PMID 9094188.
  21. information at the Histiocytosis Association of America
  22. Bieliauskas S, Tubbs RR, Bacon CM, Eshoa C, Foucar K, Gibson SE, Kroft SH, Sohani AR, Swerdlow SH, Cook JR (April 2012). “Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases”. Am. J. Surg. Pathol. 36 (4): 534–43. doi:10.1097/PAS.0b013e318240590a. PMC 3715127. PMID 22301495.
  23. Vilendecic M, Grahovac G, Lambasa S, Jelec V, Topic I (February 2012). “Unrecognized hemangiopericytoma of posterior cervical region with intracranial extension”. J Craniomaxillofac Surg. 40 (2): e51–3. doi:10.1016/j.jcms.2011.01.019. PMID 21345688.
  24. Pospelova TI, Koptev VD, Volkova II, Loseva MI, Ageeva TA, Soldatova GS (2008). “[The stage of portal blood flow in patients with hemoblastosis combined with chronic hepatitis]”. Klin Med (Mosk) (in Russian). 86 (4): 55–8. PMID 18494289.
  25. Edelbroek JR, Vermeer MH, Jansen PM, Stoof TJ, van der Linden MM, Horváth B, van Baarlen J, Willemze R (December 2012). “Langerhans cell histiocytosis first presenting in the skin in adults: frequent association with a second haematological malignancy”. Br. J. Dermatol. 167 (6): 1287–94. doi:10.1111/j.1365-2133.2012.11169.x. PMID 22835048.
  26. Bennett L. Listeria monocytogenes. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2009:chap 207
  27. Gallegos M, Bradly D, Jakate S, Keshavarzian A (July 2012). “Lymphogranuloma venereum proctosigmoiditis is a mimicker of inflammatory bowel disease”. World J. Gastroenterol. 18 (25): 3317–21. doi:10.3748/wjg.v18.i25.3317. PMID 22783058.
  28. 28.0 28.1 Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R (September 2012). “Molecular pathogenesis of Waldenstrom’s macroglobulinemia”. Haematologica. 97 (9): 1281–90. doi:10.3324/haematol.2012.068478. PMC 3436227. PMID 22773606.
  29. Do PC, Nussbaum E, Moua J, Chin T, Randhawa I (May 2013). “Clinical significance of respiratory isolates for Mycobacterium abscessus complex from pediatric patients”. Pediatr. Pulmonol. 48 (5): 470–80. doi:10.1002/ppul.22638. PMID 22833551.
  30. Pulsoni A, Anghel G, Falcucci P, Matera R, Pescarmona E, Ribersani M, Villivà N, Mandelli F (January 2002). “Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review”. Am. J. Hematol. 69 (1): 67–71. PMID 11835335.
  31. NP-C Guidelines Working Group, Wraith JE, Baumgartner MR, Bembi B, Covanis A, Levade T, Mengel E, et al. Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab. 2009;98:152-165
  32. Tang LM, Hsi MS, Ryu SJ, Minauchi Y (December 1983). “Syndrome of polyneuropathy, skin hyperpigmentation, oedema and hepatosplenomegaly”. J. Neurol. Neurosurg. Psychiatry. 46 (12): 1108–14. PMC 491776. PMID 6663309.
  33. Ongrádi J, Kövesdi V, Medveczky GP (March 2010). “[Human herpesvirus 6]”. Orv Hetil (in Hungarian). 151 (13): 523–32. doi:10.1556/OH.2010.28848. PMID 20304745.

Template:WH Template:WS

Differentiating Lymphadenopathy from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [4]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[5] Ogechukwu Hannah Nnabude, MD

Overview

Lymphadenopathy can be caused by different disease categories include: neoplasms, such as lymphoma; bacterial, viral, and parasite diseases; and inflammatory conditions, such as systemic lupus erythematosus.

Differentiating different causes of Lymphadenopathy

Lymphadenopathy can be caused by different disease categories include: neoplasms such as lymphoma; bacterial, viral, and parasites diseases; and inflammatory conditions, such as systemic lupus erythematosus.

Different causes of Lymphadenopathy can be differentiated from each other based on their different clinical manifestation such as pain, constitutional symptoms; and para clinical symptoms such as blood test and pathology on biopsy.

Diseases Clinical manifestations Para-clinical findings Pathogonomic finding
Symptoms
Lab Findings Biopsy
Painless or painful Lymphadenopathy Generalized or localized Lymphadenopathy Fever Weight loss Night Sweats Rash Other symptoms Immunochemistry Blood work
NEOPLASMS
Non-Hodgkins lymphoma Painless Generalized + + + +
  • N/A
Hodgkin’s disease[1][2][3][4] Painless Generalized + + + +
  • N/A

Fine-needle aspiration

Chronic lymphocytic leukemia[5][6][7][8] Painless Generalized + + +

CBC

On microscopic histopathological analysis:
  • N/A
Small cell carcinoma of the lung[9][10][11][12][13] Painless Localized

Nearly all SCLC are immunoreactive for

Neuroendocrine and neural differentiation result in the expression of molecules like

  • N/A
  • N/A
Melanoma[14][15][16] Painless Localized
  • N/A
  • An excisional biopsy (either elliptical, punch, or saucerization) of the thickest portion of the lesion with 1-3 mm margins.
  • Epidermal atrophy and flattening and prominent dermal invasion
Lymphomatoid granulomatosis[17][18][19][20][21][22][23] Painless Generalized or localized + + +
  • N/A

CBC

  • N/A
  • On chest CT scan, Halo sign is seen due to the angioinvasive nature of the disease
Angioimmunoblastic lymphadenopathy[24][25][26][27] Painless Generalized + + + +
  • Immunophenotyping
  • Fluorescence in situ hybridization (FISH)
Lymph node or extranodal tissue biopsy is diagnostic of angioimmunoblastic T-cell lymphoma.
  • Epstein–Barr virus (EBV) has been found in both reactive B-cells and the neoplastic T-cells.
  • Trisomy 3, trisomy 5, and +X are the most frequent chromosomal abnormalities found in cases.
Giant lymph node hyperplasia (Castleman disease)[28] Painless Localized + +
  • N/A
  • N/A
  • Hypersecretion of the cytokine IL-6.
Diseases Lymphadenopathy Fever Weight loss Night sweats Rash Other symptoms Immunochemistry Blood work Biopsy

Histopathology

Pathogonomical

findings

INFECTIONS
Bacteria Syphilis[29][30][31][32] Painless Localized + + Primary syphilis:
  • Chancer

Secondary syphilis:

Tertiary syphilis

  • Gumma
  • Organ system involvement
  • Darkfield microscopy to detect T. pallidum.
  • Nontreponemal tests (e.g., VDRLand RPR )
  • Treponemal tests (e.g. FTA-ABS, the TP-PA assay
  • N/A

On microscopic histopathological analysis, characteristic findings of syphilis:

  • Mononuclear leukocytic infiltration, macrophages, and lymphocytes.
  • Swelling and proliferation of small blood vessels.
  • Painless clean base chancre.
Brucellosis[33][34][35][36][37] Painful Localized + +
  • Brucella is most commonly isolated from blood cultures
  • N/A
  • N/A
  • Night sweats, often with characteristic smell, likened to wet hay
Viral Infectious mononucleosis[38] Painful Localized + +
  • A positive reaction to a mono spot test
  • Direct detection of EBV in blood or lymphoid tissues
  • N/A
CMV[39][40] Painful Localized + +
  • Owl Eye inclusion bodies.
HIV[41][42][43][44] Painful or painless Generalized or localized +
  • Anaemia
  • Thrombocytopenia
  • Leukopenia
  • N/A
  • Plasma HIV RNA viral load
Cat scratch disease[45][46][47][48] Painful Localized + +
  • N/A
Mycobacteria Tuberculosis[49][50][51][52][53] Painful Generalized or localized + + + +
Parasite Toxoplasmosis[54][55][56][57] Painless Generalized or localized + +
  • N/A
Diseases Lymphadenopathy Fever Weight loss Night sweats Rash Other symptoms Immunochemistry Blood work Biopsy

Histopathology

Pathogonomical

findings

AUTOIMMUNE
Systemic lupus erythematosus

(SLE)[58][59][60][61]

Painless Generalized or localized + +/- +
Sjögren’s syndrome[62][63][64][65] Painless Generalized or localized +
  • N/A
Sarcoidosis[66][67][68] Painless Generalized
  • Serum ACE level
  • N/A
Biopsy of lung

References

  1. Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers. Cambridge University Press. 1994. pp. 97–. ISBN 978-0-521-47154-1.
  2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. (Dec 15, 2012). “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010”. Lancet. 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. OCLC 23245604.
  3. Shishodia S, Aggarwal BB (2004). “Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer”. Cancer Treat Res. 119: 139–73. PMID 15164877.
  4. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K; et al. (1996). “High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells”. Blood. 87 (10): 4340–7. PMID 8639794.
  5. Nabhan C, Rosen ST (2014). “Chronic lymphocytic leukemia: a clinical review”. JAMA. 312 (21): 2265–76. doi:10.1001/jama.2014.14553. PMID 25461996.
  6. Hallek M (2015). “Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment”. Am J Hematol. 90 (5): 446–60. doi:10.1002/ajh.23979. PMID 25908509.
  7. Chronic Lymphocytic Leukemia. Libre Pathology (2015) http://librepathology.org/wiki/index.php/B_cell_small_lymphocytic_lymphoma/chronic_lymphocytic_leukemia Accessed on October, 12 2015
  8. Hallek M (2015). “Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment”. Am J Hematol. 90 (5): 446–60. doi:10.1002/ajh.23979. PMID 25908509.
  9. Zakowski, Maureen F. (2003). “Pathology of small cell carcinoma of the lung”. Seminars in Oncology. 30 (1): 3–8. doi:10.1053/sonc.2003.50015. ISSN 0093-7754.
  10. National Cancer Institute: PDQ® Small Cell Lung Cancer Treatment. Bethesda, MD: National Cancer Institute. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional.
  11. Grace K. Dy & Alex A. Adjei (2002). “Novel targets for lung cancer therapy: part I”. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20 (12): 2881–2894. PMID 12065566. Unknown parameter |month= ignored (help)
  12. K. Hibi, T. Takahashi, Y. Sekido, R. Ueda, T. Hida, Y. Ariyoshi, H. Takagi & T. Takahashi (1991). “Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer”. Oncogene. 6 (12): 2291–2296. PMID 1722571. Unknown parameter |month= ignored (help)
  13. Yuri Pekarsky, Alexey Palamarchuk, Kay Huebner & Carlo M. Croce (2002). “FHIT as tumor suppressor: mechanisms and therapeutic opportunities”. Cancer biology & therapy. 1 (3): 232–236. PMID 12432269. Unknown parameter |month= ignored (help)
  14. Miller AJ, Mihm MC (2006). “Melanoma”. N Engl J Med. 355 (1): 51–65. doi:10.1056/NEJMra052166. PMID 16822996.
  15. Schanderdorf D, Kochs C, Livingstone E (2013). Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment. Springer.
  16. Mooi W, Krausz T (2007). Pathology of Melanocytic Disorders 2nd Ed. CRC Press.
  17. Denburg JA, Bienenstock J (March 1979). “Physiology of the immune response”. Can Fam Physician. 25: 301–7. PMC 2382958. PMID 21297689.
  18. Jaffe ES, Wilson WH (1997). “Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications”. Cancer Surv. 30: 233–48. PMID 9547995.
  19. Schmoldt A, Benthe HF, Haberland G (1975). “Digitoxin metabolism by rat liver microsomes”. Biochem Pharmacol. 24 (17): 1639–41. PMC 5922622. PMID https://doi.org/10.1016/S0046-8177(72)80005-4 Check |pmid= value (help).
  20. Beaty MW, Toro J, Sorbara L, Stern JB, Pittaluga S, Raffeld M; et al. (2001). “Cutaneous lymphomatoid granulomatosis: correlation of clinical and biologic features”. Am J Surg Pathol. 25 (9): 1111–20. PMID 11688570.
  21. Bartosik W, Raza A, Kalimuthu S, Fabre A (2012). “Pulmonary lymphomatoid granulomatosis mimicking lung cancer”. Interact Cardiovasc Thorac Surg. 14 (5): 662–4. doi:10.1093/icvts/ivr083. PMC 3329320. PMID 22361129.
  22. Colby TV (2012). “Current histological diagnosis of lymphomatoid granulomatosis”. Mod Pathol. 25 Suppl 1: S39–42. doi:10.1038/modpathol.2011.149. PMID 22214969.
  23. Hare SS, Souza CA, Bain G, Seely JM, Gomes MM; et al. (2012). “The radiological spectrum of pulmonary lymphoproliferative disease”. Br J Radiol. 85 (1015): 848–64. doi:10.1259/bjr/16420165. PMC 3474050. PMID 22745203.
  24. Swerdlow, S.H.; Campo, E.; Harris, N.L.; Jaffe, E.S.; Pileri, S.A.; Stein, H.; Thiele, J.; Vardiman, J.W (2008). “11 Mature T- and NK-cell neoplasms: Angioimmunoblastic T-cell lymphoma”. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC WHO Classification of Tumours. 2 (4th ed.). IARC. ISBN 9283224310.
  25. [1] Quintanilla-Martinez L, Fend F, Moguel LR, Spilove L, Beaty MW, Kingma DW, Raffeld M, Jaffe ES. “Peripheral T-cell lymphoma with Reed-Sternberg-like cells of B-cell phenotype and genotype associated with Epstein-Barr virus infection.” Am J Surg Pathol. 1999 Oct;23(10):1233-40. PMID: 10524524
  26. [2] Ree HJ, Kadin ME, Kikuchi M, Ko YH, Go JH, Suzumiya J, Kim DS. “Angioimmunoblastic lymphoma (AILD-type T-cell lymphoma) with hyperplastic germinal centers.” Am J Surg Pathol. 1998 Jun;22(6):643-55. PMID: 9630171
  27. [3] Kaneko Y, Maseki N, Sakurai M, Takayama S, Nanba K, Kikuchi M, Frizzera G. “Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive “angioimmunoblastic lymphadenopathy with dysproteinemia-type” features.” Blood. 1988 Aug;72(2):413-21. PMID: 3261178
  28. Aoki Y, Yarchoan R, Wyvill K, Okamoto S, Little RF, Tosato G. Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood 2001;97(7):2173-6.
  29. Carlson JA, Dabiri G, Cribier B, Sell S (2011). “The immunopathobiology of syphilis: the manifestations and course of syphilis are determined by the level of delayed-type hypersensitivity”. Am J Dermatopathol. 33 (5): 433–60. doi:10.1097/DAD.0b013e3181e8b587. PMC 3690623. PMID 21694502.
  30. Fitzgerald TJ (1992). “The Th1/Th2-like switch in syphilitic infection: is it detrimental?”. Infect Immun. 60 (9): 3475–9. PMC 257347. PMID 1386838.
  31. Singh AE, Romanowski B (1999). “Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features”. Clin Microbiol Rev. 12 (2): 187–209. PMC 88914. PMID 10194456.
  32. Engelkens HJ, ten Kate FJ, Vuzevski VD, van der Sluis JJ, Stolz E (1991). “Primary and secondary syphilis: a histopathological study”. Int J STD AIDS. 2 (4): 280–4. PMID 1911961.
  33. Pappas G, Akritidis N, Bosilkovski M, Tsianos E (2005). “Brucellosis”. N Engl J Med. 352 (22): 2325–36. doi:10.1056/NEJMra050570. PMID 15930423.
  34. Zhan Y, Liu Z, Cheers C (1996). “Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisms”. Infect Immun. 64 (7): 2782–6. PMC 174139. PMID 8698508.
  35. Gazapo E, Gonzalez Lahoz J, Subiza JL, Baquero M, Gil J, de la Concha EG (1989). “Changes in IgM and IgG antibody concentrations in brucellosis over time: importance for diagnosis and follow-up”. J Infect Dis. 159 (2): 219–25. PMID 2915152.
  36. Arenas GN, Staskevich AS, Aballay A, Mayorga LS (2000). “Intracellular trafficking of Brucella abortus in J774 macrophages”. Infect Immun. 68 (7): 4255–63. PMC 101738. PMID 10858243.
  37. Lapaque N, Moriyon I, Moreno E, Gorvel JP (2005). “Brucella lipopolysaccharide acts as a virulence factor”. Curr Opin Microbiol. 8 (1): 60–6. doi:10.1016/j.mib.2004.12.003. PMID 15694858.
  38. Chapman AL, Watkin R, Ellis CJ (2002). “Abdominal pain in acute infectious mononucleosis”. BMJ. 324 (7338): 660–1. doi:10.1136/bmj.324.7338.660. PMID 11895827.
  39. Griffiths P, Lumley S (2014). “Cytomegalovirus”. Curr Opin Infect Dis. 27 (6): 554–9. doi:10.1097/QCO.0000000000000107. PMID 25304390.
  40. Pytka D, Czarkowska-Pączek B (2016). “[CMV infection in elderly]”. Przegl Lek. 73 (4): 241–4. PMID 27526428.
  41. Pantaleo G, Graziosi C, Fauci AS (1993). “New concepts in the immunopathogenesis of human immunodeficiency virus infection”. N Engl J Med. 328 (5): 327–35. doi:10.1056/NEJM199302043280508. PMID 8093551.
  42. Coovadia, H. (2004). “Antiretroviral agents—how best to protect infants from HIV and save their mothers from AIDS”. N. Engl. J. Med. 351 (3): 289–292. PMID 15247337.
  43. Lifson AR (1988). “Do alternate modes for transmission of human immunodeficiency virus exist? A review”. JAMA. 259 (9): 1353–6. PMID 2963151.
  44. WHO (2007). “WHO and UNAIDS announce recommendations from expert consultation on male circumcision for HIV prevention”. WHO.int. Retrieved 2007-07-13.
  45. Chomel BB; Kasten RW; Floyd-Hawkins K; et al. (1996). “Experimental transmission of Bartonella henselae by the cat flea”. J. Clin. Microbiol. 34 (8): 1952–6. PMC 229161. PMID 8818889. Unknown parameter |month= ignored (help); Unknown parameter |author-separator= ignored (help)
  46. Higgins JA, Radulovic S, Jaworski DC, Azad AF (1996). “Acquisition of the cat scratch disease agent Bartonella henselae by cat fleas (Siphonaptera:Pulicidae)”. J. Med. Entomol. 33 (3): 490–5. PMID 8667399. Unknown parameter |month= ignored (help)
  47. Telford SR III, Wormser GP (2010). “Bartonella spp. transmission by ticks not established”. Emerg Infect Dis. 16 (3): 379–84. doi:10.3201/eid1603.090443. PMID 20202410. Unknown parameter |month= ignored (help)
  48. Foil L; Andress E; Freeland RL; et al. (1998). “Experimental infection of domestic cats with Bartonella henselae by inoculation of Ctenocephalides felis (Siphonaptera: Pulicidae) feces”. J. Med. Entomol. 35 (5): 625–8. PMID 9775583. Unknown parameter |month= ignored (help); Unknown parameter |author-separator= ignored (help)
  49. Herrmann J, Lagrange P (2005). “Dendritic cells and Mycobacterium tuberculosis: which is the Trojan horse?”. Pathol Biol (Paris). 53 (1): 35–40. PMID 15620608.
  50. Silva Miranda M, Breiman A, Allain S, Deknuydt F, Altare F (2012). “The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria?”. Clin Dev Immunol. 2012: 139127. doi:10.1155/2012/139127. PMC 3395138. PMID 22811737.
  51. Silva Miranda M, Breiman A, Allain S, Deknuydt F, Altare F (2012). “The tuberculous granuloma: an unsuccessful host defence mechanism providing a safety shelter for the bacteria?”. Clin Dev Immunol. 2012: 139127. doi:10.1155/2012/139127. PMC 3395138. PMID 22811737.
  52. Lawn SD, Zumla AI (2011). “Tuberculosis”. Lancet. 378 (9785): 57–72. doi:10.1016/S0140-6736(10)62173-3. PMID 21420161.
  53. Zumla A, Raviglione M, Hafner R, von Reyn CF (2013). “Tuberculosis”. N Engl J Med. 368 (8): 745–55. doi:10.1056/NEJMra1200894. PMID 23425167.
  54. Wolf A, Cowen D, Paige BH (1940). “TOXOPLASMIC ENCEPHALOMYELITIS : IV. EXPERIMENTAL TRANSMISSION OF THE INFECTION TO ANIMALS FROM A HUMAN INFANT”. J Exp Med. 71 (2): 187–214. PMC 2135077. PMID 19870956.
  55. FRENKEL JK (1949). “Pathogenesis, diagnosis and treatment of human toxoplasmosis”. J Am Med Assoc. 140 (4): 369–77. PMID 18128617.
  56. Frenkel JK (1974). “Pathology and pathogenesis of congenital toxoplasmosis”. Bull N Y Acad Med. 50 (2): 182–91. PMC 1749352. PMID 4592096.
  57. Conley FK, Jenkins KA, Remington JS (1981). “Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections”. Hum Pathol. 12 (8): 690–8. PMID 7026410.
  58. Elkon K (1995). “Autoantibodies in systemic lupus erythematosus”. Curr Opin Rheumatol. 7 (5): 384–8. PMID 8519610.
  59. Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, Komisar O, Slonimsky E, Klang E, Lotan E, Welt M, Marai I, Shina A, Amital H, Shoenfeld Y (2015). “A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients”. Autoimmun Rev. 14 (1): 75–9. doi:10.1016/j.autrev.2014.10.003. PMID 25449682.
  60. Dye JR, Ullal AJ, Pisetsky DS (2013). “The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus”. Scand. J. Immunol. 78 (2): 140–8. doi:10.1111/sji.12068. PMID 23672591.
  61. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK (2004). “Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus”. Arthritis Rheum. 50 (12): 3958–67. doi:10.1002/art.20798. PMID 15593221.
  62. Ramos-Casals M, Brito-Zerón P, Solans R, Camps MT, Casanovas A, Sopeña B, Díaz-López B, Rascón FJ, Qanneta R, Fraile G, Pérez-Alvarez R, Callejas JL, Ripoll M, Pinilla B, Akasbi M, Fonseca E, Canora J, Nadal ME, de la Red G, Fernández-Regal I, Jiménez-Heredia I, Bosch JA, Ayala MD, Morera-Morales L, Maure B, Mera A, Ramentol M, Retamozo S, Kostov B (February 2014). “Systemic involvement in primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)”. Rheumatology (Oxford). 53 (2): 321–31. doi:10.1093/rheumatology/ket349. PMID 24162151.
  63. Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E, Barton J, Carlson A, Margaretten M, Zell J, Gensler LS, Kelly V, Saag K, King C (March 2013). “Choosing wisely: the American College of Rheumatology’s Top 5 list of things physicians and patients should question”. Arthritis Care Res (Hoboken). 65 (3): 329–39. doi:10.1002/acr.21930. PMC 4106486. PMID 23436818.
  64. Beckman KA, Luchs J, Milner MS (2016). “Making the diagnosis of Sjögren’s syndrome in patients with dry eye”. Clin Ophthalmol. 10: 43–53. doi:10.2147/OPTH.S80043. PMC 4699514. PMID 26766898.
  65. Both T, Dalm VA, van Hagen PM, van Daele PL (2017). “Reviewing primary Sjögren’s syndrome: beyond the dryness – From pathophysiology to diagnosis and treatment”. Int J Med Sci. 14 (3): 191–200. doi:10.7150/ijms.17718. PMC 5370281. PMID 28367079.
  66. Iannuzzi MC, Rybicki BA, Teirstein AS: Sarcoidosis. N Engl J Med 357:2153–2165, 2007.
  67. Zissel G: Cellular activation in the immune response of sarcoidosis. Semin Respir Crit Care Med 35:307–315, 2014.
  68. Rosen Y: Pathology of sarcoidosis. Semin Respir Crit Care Med 28(1):36–52, 2007.

Template:WH Template:WS

Epidemiology and Demographics
Laboratory Evaluation of Lymphadenopathy

Laboratory Evaluation of Lymphadenopathy

Diagnostic Radiological Testing

Diagnostic Radiological Testing

Treatment

Treatment

References

References



Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH